Resources
Browse our scientific resource library
Guides, briefs, data sheets, posters, videos, and event listings from our platform work, customer programs, and conference appearances. Filter by type to find what you need.
Filter by
White Paper
Multispecific Antibodies
Modular Multispecific Antibodies: The Plug-and-Play Advantage of Invenra's B-Body® and T-Body™ Platforms
How Invenra’s platforms enable easy assembly and format-agnostic purification.
Slide Deck
T-cell Engagers
T-Body Trispecific TAA/CD3/CD28 Co-Stimulatory Antibody Optimization Drives Superior Tumor-Directed T-Cell Engagement
Producing more potent, less exhausted, and potentially safer anti-tumor responses.
Poster
Bispecific Antibodies
Enabling Rapid Bispecific Antibody Discovery with Invenra’s B-Body Platform
Combining optimized phage libraries and high-throughput matrix screening to deliver clinical-ready bispecific leads in under four months.
Data Sheet
Antibody Expression
Rapid Express Antibody Expression
Producing high-purity monoclonal and bispecific antibodies at screening and validation scales in as little as eight weeks.
Data Sheet
Antibody Expression
Rapid Antibody Expression Services
Accelerating monoclonal and bispecific antibody discovery through streamlined workflows and proprietary phage display technology.
Data Sheet
Bispecific Antibodies
The B-Body Bispecific Platform
Delivering high-yield, soluble, low-viscosity bispecific antibodies designed for efficient manufacturing and subcutaneous delivery.
Data Sheet
Trispecific Antibodies
The T-Body Trispecific Platform
Enabling modular assembly of high-purity trispecific antibodies with robust expression and IgG-like properties.
Slide Deck
T-cell engagers
Engineering Trispecific CD3×CD28 T-Cell Engagers: Systematic Optimization of Affinity, Format, and Co-Stimulation
Accelerating the discovery and optimization of novel multispecifics for complex diseases like solid tumors.
Slide Deck
Antibody-Drug Conjugates
From Bi- to Trispecific Antibodies: Reimagining the Next Generation of ADCs
Engineering next-generation trispecific ADCs to address tumor heterogeneity, dense stroma, and narrow therapeutic windows.
Slide Deck
Antibody-Drug Conjugates
12x12 Matrix Screening with B-Body® and T-Body Platforms: Comprehensive, Rapid Discovery of Multispecific Antibodies for ADCs Targeting Breast Cancer
Using rapid 12×12 matrix screening to identify multispecific ADCs with superior activity across heterogeneous breast cancer models.
Slide Deck
Trispecific Antibodies
T-Body: A Novel Trispecific Antibody Platform to Accelerate and De-Risk Drug Discovery
Combining manufacturable IgG-like formats with rapid matrix screening to accelerate and de-risk multispecific ADC development.
